Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1982 Jun 26;284(6333):1908–1911. doi: 10.1136/bmj.284.6333.1908

Bromocriptine in management of large pituitary tumours.

J A Wass, J Williams, M Charlesworth, D P Kingsley, A M Halliday, I Doniach, L H Rees, W I McDonald, G M Besser
PMCID: PMC1498802  PMID: 6805756

Abstract

Bromocriptine has an accepted place in the management of small pituitary tumours that secrete either prolactin or growth hormone. The treatment of large tumours with extrasellar extensions is more difficult, however: though surgery is the standard treatment, it is often unsuccessful in returning excessive hormone secretion to normal and may cause hypopituitarism. A prospective trial was undertaken to assess the frequency with which changes in pituitary function and size of large tumours occurs. Nineteen patients were studied before and during treatment with bromocriptine (7.5 to 60 ml/day) for three to 22 months, using contrast radiology and a detailed assessment of pituitary function. Eighteen patients had hyperprolactinaemia and two of these also had raised concentrations of growth hormones; one patient had an apparently non-functioning tumour. In 12 patients (63%) tumour size decreased with bromocriptine and no tumour enlarged. Nine patients had visual-field defects, which improved in seven, becoming normal in five. Pituitary function improved in nine patients (47%) becoming entirely normal in three. Bromocriptine should be the treatment of choice in patients with large pituitary tumours with extrasellar extensions, provided close supervision is maintained.

Full text

PDF
1908

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belforte L., Camanni F., Chiodini P. G., Liuzzi A., Massara F., Molinatti G. M., Müller E. E., Silvestrini F. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. Acta Endocrinol (Copenh) 1977 Jun;85(2):235–248. doi: 10.1530/acta.0.0850235. [DOI] [PubMed] [Google Scholar]
  2. Besser G. M., Parke L., Edwards C. R., Forsyth I. A., McNeilly A. S. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972 Sep 16;3(5828):669–672. doi: 10.1136/bmj.3.5828.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blumenhardt L. D., Halliday A. M. Hemisphere contributions to the composition of the pattern-evoked potential waveform. Exp Brain Res. 1979 Jun 1;36(1):53–69. doi: 10.1007/BF00238467. [DOI] [PubMed] [Google Scholar]
  4. CLARK F., HORN D. B. ASSESSMENT OF THYROID FUNCTION BY THE COMBINED USE OF THE SERUM PROTEIN-BOUND IODINE AND RESIN UPTAKE OF 131-I-TRIIODOTHYRONINE. J Clin Endocrinol Metab. 1965 Jan;25:39–45. doi: 10.1210/jcem-25-1-39. [DOI] [PubMed] [Google Scholar]
  5. Carter J. N., Tyson J. E., Tolis G., Van Vliet S., Faiman C., Friesen H. G. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med. 1978 Oct 19;299(16):847–852. doi: 10.1056/NEJM197810192991602. [DOI] [PubMed] [Google Scholar]
  6. Chiodini P., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Luccarelli G. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab. 1981 Oct;53(4):737–743. doi: 10.1210/jcem-53-4-737. [DOI] [PubMed] [Google Scholar]
  7. Dorrell D. The tilted disc. Br J Ophthalmol. 1978 Jan;62(1):16–20. doi: 10.1136/bjo.62.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forsyth I. A., Besser G. M., Edwards C. R., Francis L., Myres R. P. Plasma prolactin activity in inappropriate lactation. Br Med J. 1971 Jul 24;3(5768):225–227. doi: 10.1136/bmj.3.5768.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Franks S., Jacobs H. S., Martin N., Nabarro J. D. Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978 Apr;8(4):277–287. doi: 10.1111/j.1365-2265.1978.tb02770.x. [DOI] [PubMed] [Google Scholar]
  10. Franks S., Nabarro J. D. Prevalence and presentation of hyperprolactinaemia in patients with "functionless" pituitary tumours. Lancet. 1977 Apr 9;1(8015):778–780. doi: 10.1016/s0140-6736(77)92959-2. [DOI] [PubMed] [Google Scholar]
  11. George S. R., Burrow G. N., Zinman B., Ezrin C. Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med. 1979 Apr;66(4):697–702. doi: 10.1016/0002-9343(79)91187-2. [DOI] [PubMed] [Google Scholar]
  12. Green J. R., Goble H. L., Edwards C. R., Dawson A. M. Reversible insensitivity to androgens in men with untreated gluten enteropathy. Lancet. 1977 Feb 5;1(8006):280–282. doi: 10.1016/s0140-6736(77)91825-6. [DOI] [PubMed] [Google Scholar]
  13. Halliday A. M., Halliday E., Kriss A., McDonald W. I., Mushin J. The pattern-evoked potential in compression of the anterior visual pathways. Brain. 1976 Jun;99(2):357–374. doi: 10.1093/brain/99.2.357. [DOI] [PubMed] [Google Scholar]
  14. Hancock K. W., Scott J. S., Lamb J. T., Gibson R. M., Chapman C. Conservative management of pituitary prolactinomas; evidence for bromocriptine-induced regression. Br J Obstet Gynaecol. 1980 Jun;87(6):523–529. doi: 10.1111/j.1471-0528.1980.tb04590.x. [DOI] [PubMed] [Google Scholar]
  15. Landolt A. M., Wüthrich R., Fellmann H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet. 1979 May 19;1(8125):1082–1083. doi: 10.1016/s0140-6736(79)92976-3. [DOI] [PubMed] [Google Scholar]
  16. Lloyd H. M., Meares J. D., Jacobi J. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells. Nature. 1975 Jun 5;255(5508):497–498. doi: 10.1038/255497a0. [DOI] [PubMed] [Google Scholar]
  17. Lucchesi B. R. Recent advances in cardiovascular pharmacology. AANA J. 1974 Oct;42(5):419–438. [PubMed] [Google Scholar]
  18. MacLeod R. M., Lehmeyer J. E. Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res. 1973 Apr;33(4):849–855. [PubMed] [Google Scholar]
  19. McGregor A. M., Scanlon M. F., Hall K., Cook D. B., Hall R. Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med. 1979 Feb 8;300(6):291–293. doi: 10.1056/NEJM197902083000606. [DOI] [PubMed] [Google Scholar]
  20. McGregor A. M., Scanlon M. F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br Med J. 1979 Sep 22;2(6192):700–703. doi: 10.1136/bmj.2.6192.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McNeilly A. S. Radioimmunoassay of human prolactin. Proc R Soc Med. 1973 Sep;66(9):863–864. doi: 10.1177/003591577306600915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mortimer C. H., Besser G. M., McNeilly A. S., Tunbridge W. M., Gomez-Pan A., Hall R. Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSH-RH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf) 1973 Oct;2(4):317–326. doi: 10.1111/j.1365-2265.1973.tb01717.x. [DOI] [PubMed] [Google Scholar]
  23. Pelkonen R., Grahne B., Hirvonen E., Karonen S. L., Salmi J., Tikkanen M., Valtonen S. Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy. Clin Endocrinol (Oxf) 1981 Apr;14(4):335–348. doi: 10.1111/j.1365-2265.1981.tb00618.x. [DOI] [PubMed] [Google Scholar]
  24. Prescott R. W., Johnston D. G., Kendall-Taylor P., Crombie A., Hall K., McGregor A., Hall R. Hyperprolactinaemia in men-response to bromocriptine therapy. Lancet. 1982 Jan 30;1(8266):245–248. doi: 10.1016/s0140-6736(82)90975-8. [DOI] [PubMed] [Google Scholar]
  25. Quadri S. K., Lu K. H., Meites J. Ergot-induced inhibition of pituitary tumor growth in rats. Science. 1972 Apr 28;176(4033):417–418. doi: 10.1126/science.176.4033.417. [DOI] [PubMed] [Google Scholar]
  26. Spark R. F., Baker R., Bienfang D. C., Bergland R. Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery? JAMA. 1982 Jan 15;247(3):311–316. [PubMed] [Google Scholar]
  27. Symon L., Jakubowski J. Transcranial management of pituitary tumours with suprasellar extension. J Neurol Neurosurg Psychiatry. 1979 Feb;42(2):123–133. doi: 10.1136/jnnp.42.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Thorner M. O., Martin W. H., Rogol A. D., Morris J. L., Perryman R. L., Conway B. P., Howards S. S., Wolfman M. G., MacLeod R. M. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab. 1980 Sep;51(3):438–445. doi: 10.1210/jcem-51-3-438. [DOI] [PubMed] [Google Scholar]
  29. Thorner M. O., McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 1974 May 25;2(5916):419–422. doi: 10.1136/bmj.2.5916.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vaidya R. A., Aloorkar S. D., Rege N. R., Maskati B. T., Jahangir R. P., Sheth A. R., Pandya S. K. Normalization of visual fields following bromocriptine treatment in hyperprolactinemic patients with visual field constriction. Fertil Steril. 1978 Jun;29(6):632–636. doi: 10.1016/s0015-0282(16)43335-2. [DOI] [PubMed] [Google Scholar]
  31. Wass J. A., Moult P. J., Thorner M. O., Dacie J. E., Charlesworth M., Jones A. E., Besser G. M. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet. 1979 Jul 14;2(8133):66–69. doi: 10.1016/s0140-6736(79)90120-x. [DOI] [PubMed] [Google Scholar]
  32. Wass J. A., Thorner M. O., Morris D. V., Rees L. H., Mason A. S., Jones A. E., Besser G. M. Long-term treatment of acromegaly with bromocriptine. Br Med J. 1977 Apr 2;1(6065):875–878. doi: 10.1136/bmj.1.6065.875. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES